Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4368382 | 0.80 | CRHBP (0.43) | CRHBPCRHR2P2RX3KDM4ETSHR | |
| SCHEMBL4363435 | 0.79 | PCSK9 (0.42) | SYKKDM4EPCSK9ALDH1A1KMT2A | |
| SCHEMBL4373507 | 0.78 | KIF11 (0.43) | CRHBPCRHR2P2RX3KDM4ETSHR | |
| SCHEMBL2736627 | 0.73 | ATM (0.56) | SYKPCSK9KMT2A | |
| SCHEMBL10238709 | 0.73 | ATM (0.56) | SYKPCSK9KMT2A | |
| SCHEMBL9894331 | 0.72 | MAPT (0.56) | KDM4ETSHRALDH1A1HPGDKMT2A | |
| SCHEMBL31558583 | 0.68 | KDM4E (0.51) | KDM4ETSHRALDH1A1HPGDKMT2A | |
| SCHEMBL1185840 | 0.68 | SYK (0.57) | SYKTSHR | |
| SCHEMBL13120820 | 0.68 | MAPK8 (0.49) | KDM4ETSHRALDH1A1KMT2ARAB9A | |
| SCHEMBL3164830 | 0.66 | MKNK2 (0.41) | SYKKDM4ETSHRALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482343-B2 | Compounds, methods and compositions | CYTOKINETICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070135432-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-7166595-B2 | Compounds, methods and compositions | CYTOKINETICS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1503993-A4 | COMPOUNDS, METHODS AND COMPOSITIONS | CYTOKINETICS INC (US) | 2006-05-03 | — | — | EP | disclosed |
| EP-1503993-A2 | COMPOUNDS, METHODS AND COMPOSITIONS | Cytokinetics, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20040077662-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003094839-A2 | PYRIMIDINONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077662-A1 | Compounds, methods and compositions | ALPP, PCNA, MKI67 | CRHBP 1777/4885CRHR2 4432/4885P2RX3 4782/4885 |
| US-20070135432-A1 | Compounds, methods and compositions | ALPP, PCNA, MKI67 | CRHBP 1777/4885CRHR2 4432/4885P2RX3 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.